

Table S1. Evolution per visit

Variable	VISIT 0 (n=98)	VISIT 1 (n=90)	VISIT 3 (n=71)	VISIT 6 (n=60)	VISIT 12 (n=38)	VISIT 18 (n=23)	VISIT 24 (n=8)
HAQ – mean (SD)	1.48 (0.52)	1.26 (0.51)	1.11 (0.52)	0.99 (0.53)	1 (0.55)	0.9 (0.57)	1.04 (0.19)
DAS28 – mean (SD)	4.86 (1.05)	3.87 (1.31)	3.31 (1.24)	2.93 (1.28)	3.19 (1.49)	3.07 (0.91)	3.42 (0.49)
Median (1st, 3rd Q.)	5.05 (4.06, 5.5)	3.8 (2.95, 4.66)	3.25 (2.34, 4.28)	2.85 (2.1, 3.53)	3 (2.14, 4.17)	3.06 (2.58, 3.63)	3.57 (3.09, 3.67)
SDAI – mean (SD)	24.98 (9.83)	16.09 (10.61)	14.27 (16.24)	10.06 (8.81)	11.06 (10.96)	7.58 (5.55)	10.28 (5.07)
Median (1st, 3rd Q.)	24.21 (19.93, 31.25)	14 (8, 22.12)	11.69 (4.53, 17.77)	8.61 (3, 14)	8.55 (3.18, 14.53)	6.29 (4.03, 11.09)	10.07 (10, 11.05)
CRP mg/L – mean (SD)	14.07 (18.02)	8.85 (18.37)	7.38 (15.1)	5.29 (7.49)	4.48 (6.32)	4.28 (4.98)	16.84 (15.75)
Median (1st, 3rd Q.)	6.1 (1.65, 19.1)	3.2 (0.7, 6.4)	2.75 (0.55, 6.58)	2.4 (0.8, 6.95)	2.05 (0.48, 6.08)	2.7 (0.8, 6.15)	20.5 (0.7, 30)
ESR mm/h – mean (SD)	31.77 (21.27)	28.42 (22.33)	23.8 (20.23)	19.77 (14.94)	20.75 (18.22)	24.21 (14.38)	40 (27.08)
Median (1st, 3rd Q.)	27 (16, 48.5)	24 (13, 39)	18 (8, 35)	17 (7, 30)	14 (8, 29.5)	22 (12, 35)	34 (31, 55)
FR	164.76 (294.91)	136.88 (208.25)	134.72 (294.35)	115.37 (144.99)	112.76 (129.64)	90 (125.3)	NaN (NA)
	35 (10, 168)	34 (10, 166.75)	28 (10, 120.75)	36.5 (10, 188.5)	49 (10, 227)	22 (11, 132.5)	NA (NA, NA)
ANTICCP	161.83 (154.57)	156.72 (152.47)	151.5 (149.37)	167.2 (151.41)	174.35 (146.73)	184.86 (158.54)	NaN (NA)
	139 (0.7, 340)	115 (0.7, 340)	117 (0.68, 340)	154 (1.1, 340)	132 (3.1, 340)	191 (41.25, 340)	NA (NA, NA)
IMC	24.59 (4.41)	25.34 (5.24)	25.28 (5.1)	23.87 (2.96)	NaN (NA)	NaN (NA)	NaN (NA)
	24.8 (21.16, 26.31)	24.86 (21.18, 27.73)	24.5 (21.55, 27.34)	23.87 (22.82, 24.92)	NA (NA, NA)	NA (NA, NA)	NA (NA, NA)
SAE	2 (2.04%)	12 (13.33%)	7 (9.86%)	5 (8.93%)	2 (5.26%)	4 (21.05%)	0 (0%)
Serious Infection	0 (0%)	4 (4.44%)	5 (7.04%)	4 (7.14%)	3 (7.89%)	3 (15.79%)	1 (20%)
Temporary Interruption	2 (2.04%)	9 (10%)	18 (25.35%)	22 (39.29%)	20 (52.63%)	12 (63.16%)	3 (60%)
Herpes Zoster infection	0 (0%)	0 (0%)	1 (1.41%)	3 (5.36%)	3 (7.89%)	3 (15.79%)	0 (0%)
Infection	5 (5.1%)	8 (8.89%)	14 (19.72%)	22 (39.29%)	23 (60.53%)	13 (68.42%)	3 (60%)

Table S2. SAE AE DETALIED PER PATIENT

Document downloaded from <http://www.elsevier.es>, day 23/01/2022. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.

Patient	JAKi	AE	SAE
Patient 1	Tofacitinib	Infections (5 respiratory tract infections, tooth abscess)*	Serious Infection (pneumonia)*
Patient 2	Baricitinib	Infections (urinary tract infection, candidiasis)	Atlanto-occipital dislocation \$
Patient 3	Baricitinib	Headache, candidiasis*	No
Patient 4	Tofacitinib	Nausea*	No
Patient 5	Tofacitinib	Urinary tract infection*	No
Patient 6	Tofacitinib	Dyspepsia, gastro-enteritis, herpes labialis*	No
Patient 7	Tofacitinib	Urinary tract infection\$	Serious Infection (Urinary tract infection) \$
Patient 8	Baricitinib	Thrombocytopenia, pneumonia*	Serious Infection (pneumonia)*
Patient 9	Baricitinib	Urinary tract infection*	No
Patient 10	Baricitinib	Respiratory tract infection*	No
Patient 11	Tofacitinib	Palpitations and chest oppression with supraventricular tachycardia\$	Yes \$
Patient 12	Tofacitinib	Dyspnea, chest oppression, oliguria and leg edema\$	Yes \$
Patient 13	Tofacitinib	Urinary tract infection, respiratory tract infection	No
Patient 14	Tofacitinib	Oral ulcers, respiratory tract infection*	No
Patient 15	Baricitinib	Herpes Zoster , respiratory tract infection	Serious Infection (pneumonia)*
Patient 16	Baricitinib	Respiratory tract infection\$	Serious Infection (pneumonia) \$
Patient 17	Baricitinib	Gripe*	No
Patient 18	Baricitinib	Herpes Zoster , Respiratory tract infection*	No

Patient 19	Tofacitinib	Respiratory tract infection*	No
Patient 20	Baricitinib	Respiratory tract infection*	No
Patient 21	Tofacitinib	Respiratory tract infection (pneumonia)*	No
Patient 22	Tofacitinib	Herpes Zoster , Bhartolinitis*	No
Patient 23	Baricitinib	Cellulitis, Urinary tract infection*	Serious Infection (cellulitis)*
Patient 24	Tofacitinib	Headache, dizziness\$	Yes \$
Patient 25	Tofacitinib	Respiratory tract infection, gripe*	No
Patient 26	Tofacitinib	Mycosis of the skin by Trichophyton mentagrophytes*	No
Patient 27	Tofacitinib	Common cold	No
Patient 28	Tofacitinib	Sweating, general malaise, chills \$	Yes \$
Patient 29	Baricitinib	Dizziness\$	Yes \$
Patient 30	Tofacitinib	Panuveitis \$	Yes \$
Patient 31	Baricitinib	Headache, dizziness, Respiratory tract infection \$	Yes \$
Patient 32	Baricitinib	Respiratory tract infection*	No
Patient 33	Baricitinib	Hypertransaminasemia*	No
Patient 34	Tofacitinib	Cellulitis*	No
Patient 35	Baricitinib	Respiratory tract infection*	No
Patient 36	Tofacitinib	Headache and nausea\$	Yes \$
Patient 37	Baricitinib	Urinary tract infection, bacterial vaginosis*	No


Patient 38	Tofacitinib	Pleuritic chest pain \$	Yes \$
Patient 39	Tofacitinib	Common cold *	No
Patient 40	Tofacitinib	Respiratory tract infection*	No
Patient 41	Tofacitinib	Polyarthralgia, nausea and vomiting\$	Yes \$
Patient 42	Tofacitinib	Headache\$	Yes \$
Patient 43	Tofacitinib	Dizziness*	No
Patient 44	Tofacitinib	Folliculitis, respiratory tract infection*	No
Patient 45	Tofacitinib	Hypertransaminasemia*	No
Patient 46	Tofacitinib	Leukopenia*	No
Patient 47	Tofacitinib	Headache and dizziness \$	Yes \$
Patient 48	Tofacitinib	Respiratory tract infection*	No
Patient 49	Baricitinib	Respiratory tract infection*	No
Patient 50	Tofacitinib	Candidiasis*	No
Patient 51	Tofacitinib	Cellulitis*	No
Patient 52	Baricitinib	Periodontitis*	No
Patient 53	Tofacitinib	Tonsillitis*	No
Patient 54	Baricitinib	Respiratory tract infection*	No

*No implicó la suspensión definitiva


§Implicó la suspensión definitiva

Mean values are expressed: Mean (SD) / n(%) Median values are expressed: Median (1st, 3rd Q.)


Graphic 1. % of patients achieving **low disease activity (LDA)** or **Remission** taking JAKi




Graphic 2. % of patients achieving **low disease activity (LDA)** or **Remission** taking Baricitinib



Graphic 3. % of patients achieving **low disease activity (LDA)** or **Remission** taking Tofacitinib



Graphic 4. % of patients in first indication achieving **low disease activity (LDA)** or **Remission**



Graphic 5. Monotherapy vs Combined therapy

